Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 116

1.

Cognitive dysfunction in diabetic rats is prevented by pyridoxamine treatment. A multidisciplinary investigation.

Kassab S, Begley P, Church SJ, Rotariu SM, Chevalier-Riffard C, Dowsey AW, Phillips AM, Zeef LAH, Grayson B, Neill JC, Cooper GJS, Unwin RD, Gardiner NJ.

Mol Metab. 2019 Oct;28:107-119. doi: 10.1016/j.molmet.2019.08.003. Epub 2019 Aug 5.

2.

Poly(I:C) source, molecular weight and endotoxin contamination affect dam and prenatal outcomes, implications for models of maternal immune activation.

Kowash HM, Potter HG, Edye ME, Prinssen EP, Bandinelli S, Neill JC, Hager R, Glazier JD.

Brain Behav Immun. 2019 Nov;82:160-166. doi: 10.1016/j.bbi.2019.08.006. Epub 2019 Aug 12.

PMID:
31415868
3.

Combined Liver and Kidney Transplantation in a Patient with Situs Inversus.

King DC, Neill JC, Anderson CD, Earl TM, Koller FL.

Am Surg. 2019 Jul 1;85(7):e328-e329. No abstract available.

PMID:
31405435
4.

Cognitive dysfunction in major depression: From assessment to novel therapies.

Atique-Ur-Rehman H, Neill JC.

Pharmacol Ther. 2019 Oct;202:53-71. doi: 10.1016/j.pharmthera.2019.05.013. Epub 2019 Jun 5. Review.

PMID:
31173838
5.

Global brain volume reductions in a sub-chronic phencyclidine animal model for schizophrenia and their relationship to recognition memory.

Doostdar N, Kim E, Grayson B, Harte MK, Neill JC, Vernon AC.

J Psychopharmacol. 2019 Oct;33(10):1274-1287. doi: 10.1177/0269881119844196. Epub 2019 May 7.

PMID:
31060435
6.

Perforated Sigmoid Diverticulitis Resulting in Subcutaneous Abscess.

Neill JC Jr, Sparkman BK, Carroll JD.

Am Surg. 2018 Aug 1;84(8):e275-e276. No abstract available.

PMID:
30841997
7.

Restrictions on drugs with medical value: Moving beyond stalemate.

Freeman TP, Mehta MA, Neill JC, Nutt DJ, Tunbridge EM, Young AH.

J Psychopharmacol. 2018 Oct;32(10):1053-1055. doi: 10.1177/0269881118798609. Epub 2018 Oct 2. No abstract available.

PMID:
30278146
8.

Evolution of a maternal immune activation (mIA) model in rats: Early developmental effects.

Murray KN, Edye ME, Manca M, Vernon AC, Oladipo JM, Fasolino V, Harte MK, Mason V, Grayson B, McHugh PC, Knuesel I, Prinssen EP, Hager R, Neill JC.

Brain Behav Immun. 2019 Jan;75:48-59. doi: 10.1016/j.bbi.2018.09.005. Epub 2018 Sep 12.

PMID:
30218784
9.

Stabilized Low-n Amyloid-β Oligomers Induce Robust Novel Object Recognition Deficits Associated with Inflammatory, Synaptic, and GABAergic Dysfunction in the Rat.

Watremez W, Jackson J, Almari B, McLean SL, Grayson B, Neill JC, Fischer N, Allouche A, Koziel V, Pillot T, Harte MK.

J Alzheimers Dis. 2018;62(1):213-226. doi: 10.3233/JAD-170489.

PMID:
29439327
10.

NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update.

Cadinu D, Grayson B, Podda G, Harte MK, Doostdar N, Neill JC.

Neuropharmacology. 2018 Nov;142:41-62. doi: 10.1016/j.neuropharm.2017.11.045. Epub 2017 Nov 28. Review.

PMID:
29196183
11.

Pharmacology of cognition: a panacea for neuropsychiatric disease?

Bailey SJ, Neill JC, Moran PM.

Br J Pharmacol. 2017 Oct;174(19):3133-3135. doi: 10.1111/bph.13956.

12.

Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: A preliminary investigation.

McLean SL, Harte MK, Neill JC, Young AM.

J Psychopharmacol. 2017 Jun;31(6):660-666. doi: 10.1177/0269881117704988. Epub 2017 Apr 26.

PMID:
28441905
13.

Partial agonism at the α7 nicotinic acetylcholine receptor improves attention, impulsive action and vigilance in low attentive rats.

Hayward A, Adamson L, Neill JC.

Eur Neuropsychopharmacol. 2017 Apr;27(4):325-335. doi: 10.1016/j.euroneuro.2017.01.013. Epub 2017 Feb 1.

PMID:
28161246
14.

Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine.

Reynolds GP, Neill JC.

J Psychopharmacol. 2016 Nov;30(11):1141-1144. Epub 2016 Sep 13. Review.

PMID:
27624147
15.

Subchronic administration of phencyclidine produces hypermethylation in the parvalbumin gene promoter in rat brain.

Fachim HA, Srisawat U, Dalton CF, Harte MK, Marsh S, Neill JC, Reynolds GP.

Epigenomics. 2016 Sep;8(9):1179-83. doi: 10.2217/epi-2016-0050. Epub 2016 Aug 16.

PMID:
27529801
16.

A systematic review comparing sex differences in cognitive function in schizophrenia and in rodent models for schizophrenia, implications for improved therapeutic strategies.

Leger M, Neill JC.

Neurosci Biobehav Rev. 2016 Sep;68:979-1000. doi: 10.1016/j.neubiorev.2016.06.029. Epub 2016 Jun 22. Review.

PMID:
27344000
17.

Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model.

Sahin C, Doostdar N, Neill JC.

Behav Brain Res. 2016 Oct 1;312:93-101. doi: 10.1016/j.bbr.2016.06.021. Epub 2016 Jun 14.

PMID:
27312268
18.

Dopamine D1 receptor activation improves PCP-induced performance disruption in the 5C-CPT by reducing inappropriate responding.

Barnes SA, Young JW, Bate ST, Neill JC.

Behav Brain Res. 2016 Mar 1;300:45-55. doi: 10.1016/j.bbr.2015.11.035. Epub 2015 Nov 30.

19.

Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology.

Neill JC, Grayson B, Kiss B, Gyertyán I, Ferguson P, Adham N.

Eur Neuropsychopharmacol. 2016 Jan;26(1):3-14. doi: 10.1016/j.euroneuro.2015.11.016. Epub 2015 Nov 19.

20.

Low attentive and high impulsive rats: A translational animal model of ADHD and disorders of attention and impulse control.

Hayward A, Tomlinson A, Neill JC.

Pharmacol Ther. 2016 Feb;158:41-51. doi: 10.1016/j.pharmthera.2015.11.010. Epub 2015 Nov 23. Review.

PMID:
26617216
21.

Postnatal Phencyclidine (PCP) as a Neurodevelopmental Animal Model of Schizophrenia Pathophysiology and Symptomatology: A Review.

Grayson B, Barnes SA, Markou A, Piercy C, Podda G, Neill JC.

Curr Top Behav Neurosci. 2016;29:403-428. doi: 10.1007/7854_2015_403. Review.

PMID:
26510740
22.

Nicotinic α7 and α4β2 agonists enhance the formation and retrieval of recognition memory: Potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders.

McLean SL, Grayson B, Marsh S, Zarroug SH, Harte MK, Neill JC.

Behav Brain Res. 2016 Apr 1;302:73-80. doi: 10.1016/j.bbr.2015.08.037. Epub 2015 Aug 30.

PMID:
26327238
23.

A systematic review and meta-analysis of cognitive remediation in early schizophrenia.

Revell ER, Neill JC, Harte M, Khan Z, Drake RJ.

Schizophr Res. 2015 Oct;168(1-2):213-22. doi: 10.1016/j.schres.2015.08.017. Epub 2015 Aug 21. Review.

PMID:
26305063
24.

Putative therapeutic targets for symptom subtypes of adult ADHD: D4 receptor agonism and COMT inhibition improve attention and response inhibition in a novel translational animal model.

Tomlinson A, Grayson B, Marsh S, Hayward A, Marshall KM, Neill JC.

Eur Neuropsychopharmacol. 2015 Apr;25(4):454-67. doi: 10.1016/j.euroneuro.2014.11.016. Epub 2014 Dec 18.

PMID:
25799918
25.

Impaired limbic cortico-striatal structure and sustained visual attention in a rodent model of schizophrenia.

Barnes SA, Sawiak SJ, Caprioli D, Jupp B, Buonincontri G, Mar AC, Harte MK, Fletcher PC, Robbins TW, Neill JC, Dalley JW.

Int J Neuropsychopharmacol. 2014 Oct 31;18(2). pii: pyu010. doi: 10.1093/ijnp/pyu010.

26.

Assessment of disease-related cognitive impairments using the novel object recognition (NOR) task in rodents.

Grayson B, Leger M, Piercy C, Adamson L, Harte M, Neill JC.

Behav Brain Res. 2015 May 15;285:176-93. doi: 10.1016/j.bbr.2014.10.025. Epub 2014 Oct 29. Review.

PMID:
25447293
27.

Pay attention to impulsivity: modelling low attentive and high impulsive subtypes of adult ADHD in the 5-choice continuous performance task (5C-CPT) in female rats.

Tomlinson A, Grayson B, Marsh S, Harte MK, Barnes SA, Marshall KM, Neill JC.

Eur Neuropsychopharmacol. 2014 Aug;24(8):1371-80. doi: 10.1016/j.euroneuro.2014.04.008. Epub 2014 May 2.

PMID:
24882551
28.

The involvement of distraction in memory deficits induced by NMDAR antagonism: relevance to cognitive deficits in schizophrenia.

Grayson B, Adamson L, Harte M, Leger M, Marsh S, Piercy C, Neill JC.

Behav Brain Res. 2014 Jun 1;266:188-92. doi: 10.1016/j.bbr.2014.03.011. Epub 2014 Mar 13.

PMID:
24632009
29.

Acute and chronic effects of NMDA receptor antagonists in rodents, relevance to negative symptoms of schizophrenia: a translational link to humans.

Neill JC, Harte MK, Haddad PM, Lydall ES, Dwyer DM.

Eur Neuropsychopharmacol. 2014 May;24(5):822-35. doi: 10.1016/j.euroneuro.2013.09.011. Epub 2013 Oct 12. Review.

PMID:
24287012
30.

First episode psychosis patients show impaired cognitive function--a study of a South Asian population in the UK.

Saleem MM, Harte MK, Marshall KM, Scally A, Brewin A, Neill JC.

J Psychopharmacol. 2013 Apr;27(4):366-73. doi: 10.1177/0269881113477746. Epub 2013 Feb 20.

PMID:
23427189
31.

The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania.

Tarazi FI, Neill JC.

Expert Opin Drug Discov. 2013 Jan;8(1):93-103. doi: 10.1517/17460441.2013.738193. Epub 2012 Nov 4. Review.

PMID:
23121334
32.

PNU-120596, a positive allosteric modulator of α7 nicotinic acetylcholine receptors, reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats.

McLean SL, Idris NF, Grayson B, Gendle DF, Mackie C, Lesage AS, Pemberton DJ, Neill JC.

J Psychopharmacol. 2012 Sep;26(9):1265-70. doi: 10.1177/0269881111431747. Epub 2011 Dec 18.

PMID:
22182741
33.

D₁ receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test.

Barnes SA, Young JW, Neill JC.

Psychopharmacology (Berl). 2012 Mar;220(1):129-41. doi: 10.1007/s00213-011-2460-8. Epub 2011 Sep 8.

34.
35.

The efficacy of sodium channel blockers to prevent phencyclidine-induced cognitive dysfunction in the rat: potential for novel treatments for schizophrenia.

Large CH, Bison S, Sartori I, Read KD, Gozzi A, Quarta D, Antolini M, Hollands E, Gill CH, Gunthorpe MJ, Idris N, Neill JC, Alvaro GS.

J Pharmacol Exp Ther. 2011 Jul;338(1):100-13. doi: 10.1124/jpet.110.178475. Epub 2011 Apr 12.

PMID:
21487071
36.

Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism.

Snigdha S, Idris N, Grayson B, Shahid M, Neill JC.

Psychopharmacology (Berl). 2011 Apr;214(4):843-53. doi: 10.1007/s00213-010-2091-5. Epub 2010 Nov 19.

PMID:
21088957
37.

PD168077, a D(4) receptor agonist, reverses object recognition deficits in rats: potential role for D(4) receptor mechanisms in improving cognitive dysfunction in schizophrenia.

Sood P, Idris NF, Cole S, Grayson B, Neill JC, Young AM.

J Psychopharmacol. 2011 Jun;25(6):792-800. doi: 10.1177/0269881110387840. Epub 2010 Nov 18.

PMID:
21088042
38.

Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia.

Damgaard T, Plath N, Neill JC, Hansen SL.

Psychopharmacology (Berl). 2011 Mar;214(2):403-13. doi: 10.1007/s00213-010-2039-9. Epub 2010 Oct 19.

PMID:
20957350
39.

Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain.

Snigdha S, Neill JC, McLean SL, Shemar GK, Cruise L, Shahid M, Henry B.

J Mol Neurosci. 2011 Mar;43(3):337-45. doi: 10.1007/s12031-010-9447-5. Epub 2010 Sep 18.

40.

Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.

Neill JC, Barnes S, Cook S, Grayson B, Idris NF, McLean SL, Snigdha S, Rajagopal L, Harte MK.

Pharmacol Ther. 2010 Dec;128(3):419-32. doi: 10.1016/j.pharmthera.2010.07.004. Epub 2010 Aug 10. Review.

PMID:
20705091
41.

Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy of cognitive dysfunction in schizophrenia.

McLean SL, Grayson B, Idris NF, Lesage AS, Pemberton DJ, Mackie C, Neill JC.

Eur Neuropsychopharmacol. 2011 Apr;21(4):333-43. doi: 10.1016/j.euroneuro.2010.06.003. Epub 2010 Jul 13.

PMID:
20630711
42.

Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.

Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW, Giethlen B, Kreilgaard M, McKinzie DL, Neill JC, Nelson DL, Nielsen SM, Poulsen MN, Schaus JM, Witten LM.

Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33. doi: 10.1017/S1461145710000659. Epub 2010 Jun 23.

PMID:
20569520
43.

Effects of asenapine, olanzapine, and risperidone on psychotomimetic-induced reversal-learning deficits in the rat.

McLean SL, Neill JC, Idris NF, Marston HM, Wong EH, Shahid M.

Behav Brain Res. 2010 Dec 25;214(2):240-7. doi: 10.1016/j.bbr.2010.05.043. Epub 2010 May 31.

PMID:
20561963
44.

Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist.

Snigdha S, Horiguchi M, Huang M, Li Z, Shahid M, Neill JC, Meltzer HY.

J Pharmacol Exp Ther. 2010 Feb;332(2):622-31. doi: 10.1124/jpet.109.156349. Epub 2009 Oct 28.

PMID:
19864614
45.

Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats.

Damgaard T, Larsen DB, Hansen SL, Grayson B, Neill JC, Plath N.

Behav Brain Res. 2010 Feb 11;207(1):144-50. doi: 10.1016/j.bbr.2009.09.048. Epub 2009 Oct 12.

PMID:
19822174
46.

Olanzapine-induced weight gain in the rat: role of 5-HT2C and histamine H1 receptors.

Kirk SL, Glazebrook J, Grayson B, Neill JC, Reynolds GP.

Psychopharmacology (Berl). 2009 Nov;207(1):119-25. doi: 10.1007/s00213-009-1639-8. Epub 2009 Aug 18.

PMID:
19688201
47.

Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat.

McLean SL, Woolley ML, Thomas D, Neill JC.

Psychopharmacology (Berl). 2009 Oct;206(3):403-14. doi: 10.1007/s00213-009-1618-0. Epub 2009 Jul 21.

PMID:
19629447
48.

Comparison of the efficacy of two anticonvulsants, phenytoin and valproate to improve PCP and d-amphetamine induced deficits in a reversal learning task in the rat.

Idris NF, Neill JC, Large CH.

Front Behav Neurosci. 2009 Jun 11;3:8. doi: 10.3389/neuro.08.008.2009. eCollection 2009.

49.

Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia.

Choi YK, Snigdha S, Shahid M, Neill JC, Tarazi FI.

J Mol Neurosci. 2009 Jul;38(3):227-35. doi: 10.1007/s12031-009-9204-9. Epub 2009 May 20.

PMID:
19455435
50.

D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia.

McLean SL, Idris NF, Woolley ML, Neill JC.

Eur Neuropsychopharmacol. 2009 Jun;19(6):440-50. doi: 10.1016/j.euroneuro.2009.01.009. Epub 2009 Mar 5.

PMID:
19268547

Supplemental Content

Loading ...
Support Center